Cephalexin sodium
Based on 9 publication(s) in Google Scholar
Cephalexin sodium is an orally active cephalosporin Antibiotic. Cephalexin sodium disrupts bacterial cell wall synthesis and inhibits the growth of susceptible Gram-positive bacteria and some Gram-negative bacteria. Cephalexin sodium induces acute renal failure when overdosed in laboratory animals. Cephalexin sodium can be used in studies related to bacterial infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 38932-40-0
- 화학식: C16H16N3NaO4S
- 분자량:369.37
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cephalexin sodium
More- Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- J Med Chem. 2021 Oct 14;64(19):14344-14357. [Abstract]
- Infect Immun. 2018 May 22;86(6):e00090-18. [Abstract]
- Biomed Res Int. 2018 Jul 2:2018:3579832. [Abstract]
- University of Texas. 2025.
- bioRxiv. 2024 May 10.
- Chemosphere. 2021 Dec:285:131417. [Abstract]
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
All Antibiotic Isoforms
More
Biological Activity
Cephalexin (30 μg per disc) sodium exhibits in vitro activity against most indole-negative Proteus sp., Escherichia coli, Salmonella sp., Shigella sp., and Paracolobactrum sp. strains, but no activity against indole-positive Proteus sp., Pseudomonas sp., or Alcaligenes sp., and partial activity against Klebsiella-Aerobacter spp. when tested via 30-μg disc assay[3].
Cephalexin (15-30 μg per disc) sodium potently inhibits most gram-positive bacteria and Neisseria sp. in vitro, with MIC values ranging from 0.16 μg/mL (Neisseria meningitidis strain Suederlin) to 200 μg/mL (Streptococcus sp. group D strain 9960), and disc-plate zones of inhibition correlating with tube dilution sensitivity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cephalexin (<10->166 mg/kg; p.o.; two doses at 1 and 5 hours post-infection) exhibits in vivo efficacy against a range of experimental gram-negative bacterial infections in mice, with ED50 values ranging from <10 mg/kg to >166 mg/kg depending on the bacterial strain[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:McAllister strain (11 to 13 g)[3]
-
Dosage:Not specified
-
Administration:p.o.; two doses at 1 and 5 hours post-infection
-
Result:Achieved an oral ED50 of 1.15 mg/kg against penicillin-sensitive S. aureus strain 3055.
Achieved an oral ED50 of 3.7 mg/kg against penicillin-resistant S. aureus strain 3074.
Achieved an oral ED50 of 1.8 mg/kg against Streptococcus pyogenes strain C203.
Achieved an oral ED50 of 58.2 mg/kg against Diplococcus pneumoniae Type I.
-
Animal Model:McAllister strain (11 to 13 g)[3]
-
Dosage:Not specified
-
Administration:p.o.; two doses at 1 and 5 hours post-infection
-
Result:Achieved an oral ED50 of 22.1 mg/kg against indole-negative Proteus sp. strain PR-4.
Achieved oral ED50 values >166 mg/kg against indole-positive Proteus sp. strains PR-9 and PR-15.
Achieved an oral ED50 of 18.9 mg/kg against Salmonella typhosa strain SA-12.
Achieved an oral ED50 of <10 mg/kg against Shigella flexneri 2b strain SH-3.
Achieved an oral ED50 of 5.2 mg/kg against Klebsiella-Aerobacter spp. strain KA-14.
Achieved an oral ED50 of 166 mg/kg against Klebsiella-Aerobacter spp. strain KA-17.
Achieved an oral ED50 of 11.7 mg/kg against Escherichia coli strain EC-14.
Achieved an oral ED50 >166 mg/kg against Escherichia coli strain EC-17.
Achieved an oral ED50 <10 mg/kg against Escherichia coli strain EC-38.
Chemical Information
-
CAS No. 38932-40-0
-
분자량 369.37
-
화학식 C16H16N3NaO4S
-
SMILES
O=C1N2[C@@](SCC(C)=C2C(O[Na])=O)([H])[C@@H]1NC([C@@H](C3=CC=CC=C3)N)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Theranostics
Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents. [Abstract]2022 Jan 1;12(3):1187-1203. PMID: 35154482 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
J Med Chem
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. [Abstract]2021 Oct 14;64(19):14344-14357. PMID: 34547896 -
Infect Immun
Identification and Characterization of the Neisseria gonorrhoeae MscS-Like Mechanosensitive Channel. [Abstract]2018 May 22;86(6):e00090-18. PMID: 29581189 -
Biomed Res Int
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]2018 Jul 2:2018:3579832. PMID: 30065936 -
-
-
Chemosphere
Insights into the degradation mechanisms and pathways of cephalexin during homogeneous and heterogeneous photo-Fenton processes. [Abstract]2021 Dec:285:131417. PMID: 34246101 -
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299
순도&문서
References
[3]. Wick WE. Cephalexin, a new orally absorbed cephalosporin antibiotic. Applied microbiology. 1967 Jul;15(4):765-9. [Content Brief]
[4]. Lode H, et al. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrobial agents and chemotherapy. 1979 Jul;16(1):1-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cephalexin sodium Related Classifications
HY-W747255 Related Classifications
Powered by Bioz